Applying the 2023 ASCO-CAP guideline updates for HER2 testing in breast cancer

contributed by Daiichi Sankyo and AstraZeneca | 01/11/2024

The 2023 ASCO-CAP guideline updates for HER2 testing in breast cancer focused on assessment and reporting practices for HER2-low (HER2 IHC 1+, IHC 2+/ISH-) expression. As HER2-low classification can impact decisions made by the clinical care team, it is important to standardize clinical practice to ensure tumors with low levels of HER2 expression are assessed and reported consistently.

Our latest application note discusses how pathology laboratories can implement the 2023 ASCO-CAP guideline update recommendations in practice, with examples from a pathologist who has already started integrating them into their institution.

>> Download app note as a PDF

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.